Thrasos Therapeutics Inc., of Montreal, said its phase II dose-ranging study of THR-184 to prevent acute kidney injury (AKI) in at-risk patients undergoing cardiac surgery showed a reduction in the incidence of AKI in patients treated with the highest dose.